252 related articles for article (PubMed ID: 31955136)
1. A long-term follow-up of rituximab treatment in 20 Chinese patients with neuromyelitis optica spectrum disorders.
Lu Q; Luo J; Hao H; Liu R; Jin H; Jin Y; Gao F
Mult Scler Relat Disord; 2020 May; 40():101933. PubMed ID: 31955136
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of different rituximab therapeutic strategies in patients with neuromyelitis optica spectrum disorders.
Novi G; Bovis F; Capobianco M; Frau J; Mataluni G; Curti E; Zuliani L; Cavalla P; Brambilla L; Annovazzi P; Repice AM; Lanzillo R; Esposito S; Benedetti L; Maietta I; Sica F; Buttari F; Malucchi S; Fenu G; Landi D; Bosa C; Realmuto S; Malentacchi M; Granella F; Signori A; Bonavita S; Uccelli A; Sormani MP;
Mult Scler Relat Disord; 2019 Nov; 36():101430. PubMed ID: 31610404
[TBL] [Abstract][Full Text] [Related]
3. Rituximab as first-line therapy in neuromyelitis optica: efficiency and tolerability.
Zéphir H; Bernard-Valnet R; Lebrun C; Outteryck O; Audoin B; Bourre B; Pittion S; Wiertlewski S; Ouallet JC; Neau JP; Ciron J; Clavelou P; Marignier R; Brassat D
J Neurol; 2015 Oct; 262(10):2329-35. PubMed ID: 26194198
[TBL] [Abstract][Full Text] [Related]
4. Effectiveness of low dose of rituximab compared with azathioprine in Chinese patients with neuromyelitis optica: an over 2-year follow-up study.
Zhang M; Zhang C; Bai P; Xue H; Wang G
Acta Neurol Belg; 2017 Sep; 117(3):695-702. PubMed ID: 28608315
[TBL] [Abstract][Full Text] [Related]
5. Long-term tolerability, safety and efficacy of rituximab in neuromyelitis optica spectrum disorder: a prospective study.
Shaygannejad V; Fayyazi E; Badihian S; Mirmosayyeb O; Manouchehri N; Ashtari F; Asgari N
J Neurol; 2019 Mar; 266(3):642-650. PubMed ID: 30635724
[TBL] [Abstract][Full Text] [Related]
6. Treatment of neuromyelitis optica and neuromyelitis optica spectrum disorders with rituximab using a maintenance treatment regimen and close CD19 B cell monitoring. A six-year follow-up.
Evangelopoulos ME; Andreadou E; Koutsis G; Koutoulidis V; Anagnostouli M; Katsika P; Evangelopoulos DS; Evdokimidis I; Kilidireas C
J Neurol Sci; 2017 Jan; 372():92-96. PubMed ID: 28017256
[TBL] [Abstract][Full Text] [Related]
7. Safety and efficacy of rituximab in neuromyelitis optica spectrum disorders (RIN-1 study): a multicentre, randomised, double-blind, placebo-controlled trial.
Tahara M; Oeda T; Okada K; Kiriyama T; Ochi K; Maruyama H; Fukaura H; Nomura K; Shimizu Y; Mori M; Nakashima I; Misu T; Umemura A; Yamamoto K; Sawada H
Lancet Neurol; 2020 Apr; 19(4):298-306. PubMed ID: 32199095
[TBL] [Abstract][Full Text] [Related]
8. Disease course, progression and activity of neuromyelitis optica (NMOSD) in patients who were treated with Rituximab, 6 and 12 months after receiving the first dose of drug, in Isfahan city.
Ashtari F; Mehdipour R; Shaygannejad V; Mansourian M
Mult Scler Relat Disord; 2019 Sep; 34():77-82. PubMed ID: 31233958
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and Safety of Rituximab Therapy in Neuromyelitis Optica Spectrum Disorders: A Systematic Review and Meta-analysis.
Damato V; Evoli A; Iorio R
JAMA Neurol; 2016 Nov; 73(11):1342-1348. PubMed ID: 27668357
[TBL] [Abstract][Full Text] [Related]
10. Peripheral CD19
Ellrichmann G; Bolz J; Peschke M; Duscha A; Hellwig K; Lee DH; Linker RA; Gold R; Haghikia A
J Neurol; 2019 Jan; 266(1):57-67. PubMed ID: 30377816
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of rituximab in multiple sclerosis and neuromyelitis optica spectrum disorder.
Ongphichetmetha T; Jitprapaikulsan J; Siritho S; Rattanathamsakul N; Detweeratham T; Prayoonwiwat N
Sci Rep; 2024 Feb; 14(1):3503. PubMed ID: 38347079
[TBL] [Abstract][Full Text] [Related]
12. Impact of Rituximab on relapse rate and disability in an Ecuadorian cohort of patients with neuromyelitis optica spectrum disorders.
Correa-Díaz EP; Torres-Herrán GE; Miño Zambrano JE; Paredes-Gonzalez V; Caiza-Zambrano FJ
Mult Scler Relat Disord; 2021 Feb; 48():102683. PubMed ID: 33338945
[TBL] [Abstract][Full Text] [Related]
13. Comparison of the efficacy of azathioprine and rituximab in neuromyelitis optica spectrum disorder: a randomized clinical trial.
Nikoo Z; Badihian S; Shaygannejad V; Asgari N; Ashtari F
J Neurol; 2017 Sep; 264(9):2003-2009. PubMed ID: 28831548
[TBL] [Abstract][Full Text] [Related]
14. Low-dosage of rituximab in Chinese patients with neuromyelitis optica spectrum disorder.
Lin J; Li X; Xue B; Tong Q; Chen Z; Zhu W; Li J; Xia J
J Neuroimmunol; 2018 Apr; 317():1-4. PubMed ID: 29501080
[TBL] [Abstract][Full Text] [Related]
15. Serious safety events in rituximab-treated multiple sclerosis and related disorders.
Vollmer BL; Wallach AI; Corboy JR; Dubovskaya K; Alvarez E; Kister I
Ann Clin Transl Neurol; 2020 Sep; 7(9):1477-1487. PubMed ID: 32767531
[TBL] [Abstract][Full Text] [Related]
16. A 5-year follow-up of rituximab treatment in patients with neuromyelitis optica spectrum disorder.
Kim SH; Huh SY; Lee SJ; Joung A; Kim HJ
JAMA Neurol; 2013 Sep; 70(9):1110-7. PubMed ID: 23897062
[TBL] [Abstract][Full Text] [Related]
17. Neuromyelitis optica spectrum disorders: long-term safety and efficacy of rituximab in Caucasian patients.
Radaelli M; Moiola L; Sangalli F; Esposito F; Barcella V; Ferrè L; Rodegher M; Colombo B; Fazio R; Martinelli V; Comi G
Mult Scler; 2016 Apr; 22(4):511-9. PubMed ID: 26199350
[TBL] [Abstract][Full Text] [Related]
18. Low-Dose Mycophenolate Mofetil for Treatment of Neuromyelitis Optica Spectrum Disorders: A Prospective Multicenter Study in South China.
Huang Q; Wang J; Zhou Y; Yang H; Wang Z; Yan Z; Long Y; Yin J; Feng H; Li C; Lu Z; Hu X; Qiu W
Front Immunol; 2018; 9():2066. PubMed ID: 30258442
[TBL] [Abstract][Full Text] [Related]
19. Analysis of the treatment of neuromyelitis optica.
Torres J; Pruitt A; Balcer L; Galetta S; Markowitz C; Dahodwala N
J Neurol Sci; 2015 Apr; 351(1-2):31-35. PubMed ID: 25727350
[TBL] [Abstract][Full Text] [Related]
20. Treatment Outcomes With Rituximab in 100 Patients With Neuromyelitis Optica: Influence of FCGR3A Polymorphisms on the Therapeutic Response to Rituximab.
Kim SH; Jeong IH; Hyun JW; Joung A; Jo HJ; Hwang SH; Yun S; Joo J; Kim HJ
JAMA Neurol; 2015 Sep; 72(9):989-95. PubMed ID: 26167726
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
